Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2013. The report details a specific share repurchase transaction executed on August 12, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 720,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,675.00 pence per share; lowest price paid was 1,662.50 pence per share.
- Treasury Holdings (Settled): 507,350,412 shares (9.37% of total issued share capital).
- Treasury Holdings (Including Unsettled): 509,460,412 shares (10.39% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,905,400,920 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 720,000 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.39% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares in issue (4,905,400,920) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current treasury share percentage (10.39% of voting rights) to assess potential dilution or buyback capacity.
- Note that the filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.